PD-1 inhibitors are part of the wider group of immune checkpoint inhibitors (ICPIs), and their use is connected with the occurrence of acute kidney injury (AKI) and, in particular, tubulointerstitial nephritis (47, 48). This evidence concerns the gene PDCD1 and interstitial nephritis.